The underlying disease being treated differentiates the extent of serious side effects and malignancies when dealing with long-term immunosuppressive treatment with adalimumab (Humira). However, a new study shows that the rates of these side effects and malignancies are low.
Infections are usually the most-oft reported. For instance, rheumatoid arthritis patients report more cellulitis.
Powered by Facebook Comments